% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Seibold:143863,
author = {P. Seibold$^*$ and A. Webb and M. E. Aguado-Barrera and D.
Azria and C. Bourgier and M. Brengues and E. Briers and R.
Bultijnck and P. Calvo-Crespo and A. Carballo and A.
Choudhury and A. Cicchetti and J. Claßen and E. Delmastro
and A. M. Dunning and R. M. Elliott and M.-P. Farcy-Jacquet
and P. Gabriele and E. Garibaldi and A. Gómez-Caamaño and
S. Gutiérrez-Enríquez and D. S. Higginson and K. Johnson
and R. Lobato-Busto and M. Mollà and A. Müller$^*$ and D.
Payne and P. Peleteiro and G. Post and T. Rancati and T.
Rattay and V. Reyes and B. S. Rosenstein and D. De Ruysscher
and M. C. De Santis and J. Schäfer and T. Schnabel and E.
Sperk and R. P. Symonds and H. Stobart and B.
Taboada-Valladares and C. J. Talbot and R. Valdagni and A.
Vega and L. Veldeman and T. Ward and C. Weißenberger and C.
M. L. West and J. Chang-Claude$^*$},
collaboration = {R. consortium},
title = {{REQUITE}: {A} prospective multicentre cohort study of
patients undergoing radiotherapy for breast, lung or
prostate cancer.},
journal = {Radiotherapy and oncology},
volume = {138},
issn = {0167-8140},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DKFZ-2019-01425},
pages = {59 - 67},
year = {2019},
abstract = {REQUITE aimed to establish a resource for multi-national
validation of models and biomarkers that predict risk of
late toxicity following radiotherapy. The purpose of this
article is to provide summary descriptive data.An
international, prospective cohort study recruited cancer
patients in 26 hospitals in eight countries between April
2014 and March 2017. Target recruitment was 5300 patients.
Eligible patients had breast, prostate or lung cancer and
planned potentially curable radiotherapy. Radiotherapy was
prescribed according to local regimens, but centres used
standardised data collection forms. Pre-treatment blood
samples were collected. Patients were followed for a minimum
of 12 (lung) or 24 (breast/prostate) months and summary
descriptive statistics were generated.The study recruited
2069 breast $(99\%$ of target), 1808 prostate $(86\%)$ and
561 lung $(51\%)$ cancer patients. The centralised,
accessible database includes: physician- (47,025 forms) and
patient- (54,901) reported outcomes; 11,563 breast photos;
17,107 DICOMs and 12,684 DVHs. Imputed genotype data are
available for 4223 patients with European ancestry (1948
breast, 1728 prostate, 547 lung). Radiation-induced
lymphocyte apoptosis (RILA) assay data are available for
1319 patients. DNA (n = 4409) and PAXgene tubes
(n = 3039) are stored in the centralised biobank.
Example prevalences of 2-year (1-year for lung) grade ≥2
CTCAE toxicities are $13\%$ atrophy (breast), $3\%$ rectal
bleeding (prostate) and $27\%$ dyspnoea (lung).The
comprehensive centralised database and linked biobank is a
valuable resource for the radiotherapy community for
validating predictive models and biomarkers.Up to half of
cancer patients undergo radiation therapy and irradiation of
surrounding healthy tissue is unavoidable. Damage to healthy
tissue can affect short- and long-term quality-of-life. Not
all patients are equally sensitive to radiation 'damage' but
it is not possible at the moment to identify those who are.
REQUITE was established with the aim of trying to understand
more about how we could predict radiation sensitivity. The
purpose of this paper is to provide an overview and summary
of the data and material available. In the REQUITE study
4400 breast, prostate and lung cancer patients filled out
questionnaires and donated blood. A large amount of data was
collected in the same way. With all these data and samples a
database and biobank were created that showed it is possible
to collect this kind of information in a standardised way
across countries. In the future, our database and linked
biobank will be a resource for research and validation of
clinical predictors and models of radiation sensitivity.
REQUITE will also enable a better understanding of how many
people suffer with radiotherapy toxicity.},
cin = {C020},
ddc = {610},
cid = {I:(DE-He78)C020-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31146072},
doi = {10.1016/j.radonc.2019.04.034},
url = {https://inrepo02.dkfz.de/record/143863},
}